<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">GALLIUM NITRATE</span><br/>(gal'li-um)<br/><span class="topboxtradename">Ganite<br/></span><b>Classifications:</b> <span class="classification">bone metabolism regulator</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>25 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>The precise mechanism is not known.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Induces hypocalcemia by inhibiting calcium resorption from bone.</p>
<h1><a name="uses">Uses</a></h1>
<p>Hypercalcemia of malignancy.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Paget's disease, painful bone metastases, adjuvant therapy for bladder cancer and lymphomas.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Severe renal impairment (serum creatinine &gt;2.5 mg/dL), lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Renal function impairment, pregnancy (category C). Safety and efficacy in children are not established.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Hypercalcemia</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 100200 mg/m<sup>2</sup>/d for 57 d, dilute in 1000 mL D5W or 0.9% NaCl and infuse continuously over 24 h<br/><br/><span class="indicationtitle">Bone Metastases</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 200 mg/m<sup>2</sup>/d for 7 d, dilute in 1000 mL D5W or 0.9% NaCl and infuse continuously over 24 h <br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><ul>
<li>Hydrate patient with oral or IV NS to produce a urine output of 2 L/d; maintain adequate hydration throughout treatment.</li>
</ul>
<p><span class="routemethod">PREPARE:</span> <span class="methodtype">Continuous:</span> Dilute each daily dose with 1000 mL NS (preferred if not contraindicated) or D5W.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Continuous:</span> Infuse over 24 h taking care to avoid rapid infusion. Control rate with infusion pump or micro-drip device.  
               </p>
<ul>
<li>Do not administer concurrently with potentially nephrotoxic drugs.</li>
</ul>
</td>
</tr>
</table>
<ul>
<li>Store IV solutions at 15°30° C (59°86° F) for 48 h or refrigerated at 2°8°
            C (36°46° F) for 7 d. Discard unused portions.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> <span class="speceff-common">Fatigue,</span> paresthesia, hyperthermia. <span class="typehead">CV:</span> Hypotension. <span class="typehead">GI:</span> <span class="speceff-common">Nausea, vomiting, diarrhea,</span> anorexia, stomatitis, dysgeusia, mucositis, metallic taste. <span class="typehead">Hematologic:</span> Anemia, granulocytopenia, thrombocytopenia. <span class="typehead">Metabolic:</span> Hypocalcemia, hypophosphatemia, hypomagnesemia. <span class="typehead">Urogenital:</span> <span class="speceff-life">Nephrotoxicity</span>, acute renal failure. <span class="typehead">Other:</span> Optic neuritis, maculopapular rash. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <span class="classification">aminoglycosides</span>, <b>amphotericin B,</b> <b>vancomycin</b> increase the risk of nephrotoxicity. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Onset:</span> 48 h. <span class="typehead">Duration:</span> 414 d after discontinuation of therapy. <span class="typehead">Distribution:</span> Concentrates in tumors; distributed to lung, skin, muscle, and heart with high concentrations in liver and kidney; not known
      if crosses placenta or is distributed into breast milk. <span class="typehead">Metabolism:</span> Not metabolized. <span class="typehead">Elimination:</span> 3571% is excreted through kidneys within first 24 h after administration. <span class="typehead">Half-Life:</span> 25111 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Monitor BUN and serum creatinine throughout therapy. Notify physician if serum creatinine exceeds 25 mg/dL;
            discontinue drug if this occurs. Also, check baseline serum calcium and serum phosphorus; follow with assessments daily and
            twice weekly, respectively.
         </li>
<li> 							Note: If hypocalcemia occurs, withhold gallium nitrate and notify physician. 						</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Learn S&amp;S of hypocalcemia (see Appendix F). Notify physician immediately if any occur.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>